U.S. markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.49
    -1.15 (-1.90%)
     
  • Gold

    1,734.20
    +11.20 (+0.65%)
     
  • Silver

    26.84
    +0.16 (+0.61%)
     
  • EUR/USD

    1.2092
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3961
    +0.0040 (+0.29%)
     
  • USD/JPY

    106.7190
    -0.0110 (-0.01%)
     
  • BTC-USD

    47,479.83
    -637.50 (-1.32%)
     
  • CMC Crypto 200

    948.43
    -38.22 (-3.87%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, ON and BOSTON, Feb. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel discussion at the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021 at 1:20pm EST. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

(PRNewsfoto/Fusion Pharmaceuticals Inc.)
(PRNewsfoto/Fusion Pharmaceuticals Inc.)

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-cowen-41st-annual-health-care-conference-301233848.html

SOURCE Fusion Pharmaceuticals Inc.